This is a observational study designed to identify risk factors for venous thromboembolism in patients with newly diagnosed acute leukemia at the time of first admission to a Hematology Ward.
Each patient will be observed for the duration of hospitalization.
Age equal to or greater than 18 years of age
New diagnosis of Acute Leukemia (APL, other AML, ALL) according to the current diagnostic criteria of the ELN 2022 for myeloid lineage (AML/APL) and ELN 2024 for lymphoid lineage (ALL)
Hospitalization in a Hematology Ward lasting at least 2 days
Signed informed consent
Ongoing therapeutic-dose anticoagulant treatment at the time of admission (i.e., dosage exceeding standard thromboprophylactic regimens)
Diagnosis of venous thromboembolism (VTE) or major bleeding (MB) occurring within 48 hours of hospital admission
The study will include patients with newly diagnosed acute leukemia at the time of first admission to a Hematology Ward.
Case-only
Prospective
Not listed
Number of patients with venous thromboembolism event during hospitalization
Cumulative incidence of the first venous thromboembolism event from hospital admission to discharge or death
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
